about
Cystatin C as a marker of GFR--history, indications, and future researchAre Canadian pediatric nephrology patients really overweight?Macrohematuria with electron-dense deposits in a 14-year-old boy with minimal change nephrotic syndrome.Long-term prognosis of hemolytic uremic syndrome and effective renal plasma flow.Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome.Neonatal renal venous thrombosis: clinical outcomes and prevalence of prothrombotic disorders.Shorter break-in period is a viable option with tighter PD catheter securing during the insertion.Albuminuria and estimated GFR 5 years after Escherichia coli O157 hemolytic uremic syndrome: an update.Cardiac tamponade in diarrhoea-positive haemolytic uraemic syndrome.Chronic renal disease is more prevalent in patients with hemolytic uremic syndrome who had a positive history of diarrhea.A child with haemolytic uraemic syndrome: do we have to care about aetiological heterogeneity?Comparison of clinical and biochemical markers of dehydration with the clinical dehydration scale in children: a case comparison trial.Skeletal findings in the first 12 months following initiation of glucocorticoid therapy for pediatric nephrotic syndromeFibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional studyThe Health Initiative Program for Kids (HIP Kids): effects of a 1-year multidisciplinary lifestyle intervention on adiposity and quality of life in obese children and adolescents--a longitudinal pilot intervention studyGlomerular filtration rate as a putative 'surrogate end-point' for renal transplant clinical trials in children.Estimation of GFR using β-trace protein in children.Evidence-based immunosuppression after pediatric renal transplantation--a dream?The Canadian Childhood Nephrotic Syndrome (CHILDNEPH) Project: overview of design and methods.Is there really an increase in non-minimal change nephrotic syndrome in children?PTHrP-related Hypercalcaemia in Infancy and Congenital Anomalies of the Kidney and Urinary Tract (CAKUT).MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients.To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription.The effect of seniority and education on departmental dictation utilization.Residual renal function calculated from serum cystatin C measurements and knowledge of the weekly standard Kt/V urea.Optimization of immunosuppressive drug monitoring in children.Should prevention of chronic kidney disease start before pregnancy?Pharmacokinetics of mycophenolate mofetil and sirolimus in children.Intravenous immunoglobulin as rescue therapy for BK virus nephropathy.Cystatin C levels in functionally anephric patients undergoing dialysis: the effect of different methods and intensities.No association between cyclosporine levels and dyslipidemia?Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome.Progress in pediatric kidney transplantation.Are we ready to use aliskiren in children?Challenges in pediatric transplantation: the impact of chronic kidney disease and cardiovascular risk factors on long-term outcomes and recommended management strategies.Prevention of chronic kidney disease in spina bifida.The usefulness of cystatin C and related formulae in pediatrics.Methods of assessing renal function.Trace elements in dialysis.Tandem hemodialysis and plasma exchange.
P50
Q28298855-2F6FD2D1-661E-4F9A-BFCC-C6EC578B6768Q30418556-6F05576E-9E01-4D18-A9B4-14CB5778EECBQ31993383-28D09F27-2B93-4A5B-BD12-534137B99FE4Q33330149-B3B25F5F-99CA-45A3-ABA0-F18F61CD72A0Q33357218-C8F25DAE-D4CC-456A-94F9-228B2300449DQ33366874-6C6A289E-3B54-4A29-979B-EA9F978218EFQ33371050-C849E47B-AB9D-41A2-AC47-E56C2EA5AC0CQ33378722-A77D4A37-DD86-4A24-B544-791F98DA3405Q33382151-D35557C6-67A0-48B1-B655-59926C603CF9Q33390187-3DF853C8-82BB-4DBA-B466-7092C64A9779Q33499437-5186057E-EA6C-4BFD-AE06-B0676604AA57Q33844536-0C0B7F3E-08C2-4454-88E9-BD42931BBD57Q33911068-7B5ED015-920D-460B-9844-AD864F8566C8Q34588377-B660895A-227C-40E0-8C13-581BDFAAA5BDQ34677342-25A317B8-79C6-4DD6-8F05-3D849BA8A075Q35064429-7370097A-CEBD-4BE6-90A4-50F91308D10CQ35144416-FC2644A9-D250-4C5C-9DA6-A520663C1639Q35552429-9F965EBD-99AD-477C-A12A-2CA36BAE32DBQ35583780-2E183ECF-3485-4FF3-967C-712399791565Q35600158-34EB64A2-81AC-4C97-AFA2-5FDFDD166CAEQ35654890-4DC67912-36B6-462E-B83F-D402C865FCBBQ35826490-70D8235E-B7E9-43F8-B488-E6DF32626897Q35838305-9F3B2604-4A4C-4790-9A30-0C1E1849D3CBQ36110821-21E3A924-3C80-4F90-BA76-A84B3172873DQ36475487-50557BF3-771E-428C-B982-36AD35641D36Q36831426-3B940C6B-384D-4E8A-8A06-9CEC9F717C0EQ37075992-060A34A3-3897-483B-9E25-25BEC2113B2FQ37119635-48D12422-055D-46CF-B710-C0685F046C41Q37281176-917C1CC8-2429-4AB6-9A74-66C37B4DE588Q37378450-282A323E-7C26-46A5-A11D-21DA1BC1798AQ37671119-AE9C6225-0356-4BFB-BE07-4D2741A55138Q37724214-9A770AC5-E80C-40F5-B0D8-FCE54330FEC0Q37739801-EAFB309D-9C04-4A92-B45D-673BFAFA2443Q37820390-F52A8B10-5797-4E0D-9561-D3F331CD99B2Q37820711-C2650F74-7404-469B-BF81-21DDE7EB07E2Q37828099-B919437D-C0E3-4529-AC5C-5F433C3DD78BQ38055057-BD322638-A0F4-450D-A7D3-29CBFFA33A1DQ38082378-077FD3BC-2944-46C2-B4AD-D39A0DED2488Q38129305-CEAFCB63-AD86-40AA-A21E-0E5A01125CA1Q38136092-AE56B7CB-65E7-41E9-9B08-951E4551CDF8
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Guido Filler
@ast
Guido Filler
@en
Guido Filler
@es
Guido Filler
@nl
Guido Filler
@sl
type
label
Guido Filler
@ast
Guido Filler
@en
Guido Filler
@es
Guido Filler
@nl
Guido Filler
@sl
prefLabel
Guido Filler
@ast
Guido Filler
@en
Guido Filler
@es
Guido Filler
@nl
Guido Filler
@sl
P214
P106
P1153
7005082763
P2038
Guido_Filler
P21
P214
P2798
P31
P3835
guido-filler
P496
0000-0003-1891-6765
P735
P7859
viaf-47593745